⌘K
Loading ticker…
Oruka Therapeutics, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Oruka Therapeutics, Inc. Common Stock (ORKA) has a 3-month relative strength percentile of 96 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 99. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.7%, relative volume 3.37×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 96, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ORKA is in a stage 2 uptrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 35.5% / 124.0%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
ORKA is held by 5 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $67M notional. Top 3 carry $151M.
Top 5 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $67M |
| IWMiShares Russell 2000 ETF | 0.06% | $46M |
| XBIState Street SPDR S&P Biotech ETF | 0.50% | $37M |
| VXFVanguard Extended Market ETF | 0.03% | $21M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $3M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ORKA Jan avg: -8.85% median: -8.85% win: 50% σ: 30.81% n: 2 2024-09-04 → 2026-05-29 | ORKA Feb avg: -12.01% median: -12.01% win: 50% σ: 17.72% n: 2 2024-09-04 → 2026-05-29 | ORKA Mar avg: 21.82% median: 21.82% win: 100% σ: 29.32% n: 2 2024-09-04 → 2026-05-29 | ORKA Apr avg: 20.61% median: 20.61% win: 100% σ: 26.67% n: 2 2024-09-04 → 2026-05-29 | ORKA May avg: -4.73% median: -4.73% win: 50% σ: 13.73% n: 2 2024-09-04 → 2026-05-29 | ORKA Jun avg: 2.28% median: 2.28% win: 100% σ: 0.00% n: 1 2024-09-04 → 2026-05-29 (current) | ORKA Jul avg: 21.23% median: 21.23% win: 100% σ: 0.00% n: 1 2024-09-04 → 2026-05-29 | ORKA Aug avg: 8.90% median: 8.90% win: 100% σ: 0.00% n: 1 2024-09-04 → 2026-05-29 | ORKA Sep avg: 13.03% median: 13.03% win: 50% σ: 23.91% n: 2 2024-09-04 → 2026-05-29 | ORKA Oct avg: 30.36% median: 30.36% win: 100% σ: 22.80% n: 2 2024-09-04 → 2026-05-29 | ORKA Nov avg: -7.77% median: -7.77% win: 50% σ: 20.68% n: 2 2024-09-04 → 2026-05-29 | ORKA Dec avg: -5.04% median: -5.04% win: 50% σ: 8.11% n: 2 2024-09-04 → 2026-05-29 |